<?xml version="1.0" encoding="UTF-8" standalone="yes"?><oembed><version><![CDATA[1.0]]></version><provider_name><![CDATA[A Blog Around The Clock]]></provider_name><provider_url><![CDATA[http://blog.coturnix.org]]></provider_url><author_name><![CDATA[Bora Zivkovic]]></author_name><author_url><![CDATA[https://blog.coturnix.org/author/coturnix/]]></author_url><title><![CDATA[Genome Technology &#8211; Open Access&nbsp;Special]]></title><type><![CDATA[link]]></type><html><![CDATA[<p>Today&#8217;s issue of Genome Technology contains six nice articles about Open Access:<br />
<a href="http://www.genome-technology.com/issues/2_19/webreprints/150414-1.html" target="_blank" title="">Ready or Not, Here Comes Open Access</a>:</p>
<blockquote><p>Here&#8217;s the central conundrum of the open access debate: you can&#8217;t find anyone who&#8217;s actually opposed to it. Really. For all the grandstanding and arguing, the fiercest opponents and supporters alike tend to support the underlying principle &#8212; that freely accessible data would be a boon to the greater scientific enterprise. In an ideal world, most everyone agrees, there would be no restrictions on scientific results. It&#8217;s the real-world practical concerns that provide the point of contention.</p></blockquote>
<p><a href="http://www.genome-technology.com/issues/2_19/webreprints/150409-1.html" target="_blank" title="">Open Access: What Does It All Mean?</a>:</p>
<blockquote><p>The pure form of open access is considered research that&#8217;s made freely available for reuse in any way another scientist might dream up. In general, as long as the original author is credited for what&#8217;s his, any other scientist can add to the work with no strings attached.</p></blockquote>
<p><a href="http://www.genome-technology.com/issues/2_19/webreprints/150412-1.html" target="_blank" title="">Many Flavors of Open Access</a>:</p>
<blockquote><p>When people refer to open access journals, there are actually a number of different models that they have in mind. Nick Fowler, head of strategy at Elsevier, breaks them down into the four main flavors.</p></blockquote>
<p><a href="http://www.genome-technology.com/issues/2_19/webreprints/150413-1.html" target="_blank" title="">An Acquisition, an Association, and a Celebration</a>:</p>
<blockquote><p>In the past month alone, the movement for open access saw a number of milestones. For starters, the group celebrated its first holiday &#8212; Open Access Day was held on October 14, with a number of organizations taking note of the occasion. Community bloggers made a special effort to raise awareness for the concept, releasing essays, videos, and other materials to introduce unfamiliar scientists to it.</p></blockquote>
<p><a href="http://www.genome-technology.com/issues/2_19/webreprints/150411-1.html" target="_blank" title="">PubMed Central: The &#8216;Mildly Destabilizing&#8217; Compromise</a>:</p>
<blockquote><p>PubMed Central has become a critical component of the scientific research landscape, but 10 years ago it was just a gleam in Harold Varmus&#8217;s eye. Originally conceived as E-Biomed, the vision was far more broad-reaching than what eventually became PubMed. &#8220;The original idea for PubMed Central was probably too radical,&#8221; Varmus says. &#8220;I probably went too far initially.&#8221;</p></blockquote>
<p><a href="http://www.genome-technology.com/issues/2_19/webreprints/150410-1.html" target="_blank" title="">Reluctant Publishers and the Birth of PLoS</a>:</p>
<blockquote><p>Pat Brown, Michael Eisen, and Harold Varmus have become the face of the Public Library of Science, but none of them ever set out to be a publisher.</p></blockquote>
<p>[Hat-tip: <a href="http://www.michaeleisen.org/blog/?p=116" target="_blank" title="">Michael Eisen</a>]</p>
]]></html></oembed>